Neoleukin Therapeutics Inc Share

$31.75

2.39%

Nasdaq, Mon, Jun 24 2024

ISIN

US64049K1043

Symbol

NLTX

Reports

Quarter | Year

Index

NASDAQ Composite

Sector

Gesundheit

Industry

Pharma

Overview Dividends Analysts Charts News Strategies

Neoleukin Therapeutics Inc Share price

$31.75

-15.85 33.30% 5Y

Nasdaq, Closing price Mon, Jun 24 2024

ISIN

US64049K1043

Symbol

NLTX

Reports

Quarter | Year

Index

NASDAQ Composite

Sector

Gesundheit

Industry

Pharma

Key figures

Market capitalization	$412.12m
Enterprise Value	$257.00m
PER (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	2.39
Turnover (TTM) Turnover	$0.00
EBIT (operating result TTM) EBIT	$-63.93m
Free cash flow (TTM) Free cash flow	$-59.54m
Cash position	$169.53m
EPS (TTM) EPS	$-2.65
P/E ratio expected	negative
Short interest	0.28%

As a free StocksGuide basic user, you can view the scores for all 6,950 shares worldwide.

Neoleukin Therapeutics Inc Share analysis

Unlock scores for free

??

6 Analysts have issued a Neoleukin Therapeutics Inc forecast:

6x Buy

100%

More details on analyst estimates including price targets

6 Analysts have issued a Neoleukin Therapeutics Inc forecast:

Buy

100%

Analyst estimates incl. share price targets

Financial data from Neoleukin Therapeutics Inc

Profit and loss account P&L | Balance sheet | Cash flow

Quarter TTM Annually

Mar '24		+/- %
Turnover	- -	- 100%
- Direct costs	3.47 3.47	35% 35% -
Gross income	-3.47 -3.47	35% 35% -
- Selling and administrative expenses	8.63 8.63	29% 29% -
- Research and development costs	48 48	27% 27% -
EBITDA	-60 -60	14% 14% -
- Depreciation and amortization	3.47 3.47	35% 35% -
EBIT (operating result) EBIT	-64 -64	15% 15% -
Net profit	-39 -39	31% 31% -

Figures in millions USD.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Subscribe to news free of charge

Neoleukin Therapeutics Inc Share News

Neutral

GlobeNewsWire

●

6 months ago

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-f...

Neutral

GlobeNewsWire

●

9 months ago

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-...

Neutral

PRNewsWire

●

11 months ago

Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene

MILWAUKEE , July 18, 2023 /PRNewswire/ -- Ademi LLP is investigating Neoleukin (Nasdaq: NLTX) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Neurogene. Click here to learn how to join the action https://www.ademilaw.com/case/neoleukin-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

More Neoleukin Therapeutics Inc News

Company profile

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Head office	United States
CEO	Rachel McMinn
Employees	91
Founded	2018
Website	www.neurogene.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

Start now